MedRxiv: Blood proteins predict poor COVID-19 results.

, June 20, 2020 /PRNewswire/ -- Low levels
of blood nephroamine can predict adverse prognosis in patients with COVID-19, yale researchers reportThey plan to apply to the U.SFDAspeed up approval to investigate whether the anti-inflammatory protein may improve the prognosis of patients with severediabetes"We wanted to investigate whether the renin enzyme protein agonist given to patients improved efficacy," said Gary Desir, senior author of theGary Desir is Professor of Medicine by Paul BBeeson, Associate Dean of Development and Diversity at Yale University School of Medicine, and President of Internal MedicinePicture Source: NIH
Desir and colleagues measured levels of nephrine in 51 PATIENTs with COVID-19 and 15 uninfected patients at Yale-New Haven HospitalThey found that 14 patients with the lowest levels of nephrine had the most severe symptoms, and were more likely to die than those with higher levels of blood proteinthe study, published in the preprint server MedRxiv, has not yet been peer-reviewedDesir's lab has previously explored the anti-inflammatory properties of using nephromine enzymes to treat acute kidney injury and acute pancreatitisDesir's theory suggests that nephrine enzymes may help reduce the devastating immune system response in cases of advanced severe COVID-19(BioValleyBioon.com) References: Blood Protein Predicts Poor COVID-19
Melinda Wang et al Diwed plasma levels of the survival factor renalase are ei fod with the worse outcomes in COVID-19 , (2020) DOI: 10.1101/2020.06.02.20120865
.